9-position Substituted Patents (Class 514/180)
  • Publication number: 20100151035
    Abstract: The present invention relates to a stable pharmaceutical composition of a poorly water-soluble drug with a view to increasing its solubility and bioavailability. The present invention relates to a solid dispersion of a poorly water-soluble drug.
    Type: Application
    Filed: March 10, 2008
    Publication date: June 17, 2010
    Applicant: Sandoz AG
    Inventors: Bharatrajan Ramaswami, Manisha Rajesh Patil, Aditi Das
  • Publication number: 20100130460
    Abstract: Disclosed are topical formulations comprising an androstane steroid, propylene glycol, and benzyl alcohol in an amount effective to dissolve the androstane steroid compound, wherein the amount of benzyl alcohol is not effective to act as a penetration enhancer. The formulations are useful for the treatment of inflammatory and/or pruritic manifestations of corticosteroid-responsive dermatoses.
    Type: Application
    Filed: December 8, 2006
    Publication date: May 27, 2010
    Applicant: Nycomed US Inc.
    Inventors: Brian Albano, Robert J. Anderson, Joseph A. Check, III, Weldon Crow
  • Publication number: 20100119587
    Abstract: The present invention relates to new compositions of (active) solid lipidic particles (SLP), e.g. for inhalation, and their use as carriers or as fillers in pharmaceutical compositions. It also relates new formulations obtained by mixing a SLP composition of the invention and a (micronized) active compound. It further relates to a method for fabricating said compositions of (active) solid lipidic particles.
    Type: Application
    Filed: December 22, 2005
    Publication date: May 13, 2010
    Applicant: UNIVERSITE LIBRE DE BRUXELLES
    Inventors: Karin Amighi, Thami Sebti
  • Patent number: 7709495
    Abstract: The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: May 4, 2010
    Assignee: CombinatoRx, Incorporated
    Inventors: Edward Roydon Jost-Price, Palaniyandi Manivasakam, Brendan Smith, Michael S. Slavonic, Benjamin A. Auspitz
  • Publication number: 20100104625
    Abstract: The present invention provides compounds of Formula I, materials comprising one or more compounds of Formula I and one or more biologically active agents, pharmaceutical compositions comprising an inventive material and a pharmaceutically acceptable excipient, methods of making compounds of Formula I, methods of making inventive materials, and methods of using pharmaceutical compositions comprising an inventive material and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: February 15, 2008
    Publication date: April 29, 2010
    Applicant: CORNELL UNIVERSITY
    Inventors: David Aaron Putnam, Sara Yazdi
  • Publication number: 20100099655
    Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.
    Type: Application
    Filed: December 23, 2009
    Publication date: April 22, 2010
    Inventors: Vernon G. Wong, Mae W.L. Hu
  • Publication number: 20100099654
    Abstract: The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.
    Type: Application
    Filed: March 13, 2008
    Publication date: April 22, 2010
    Applicant: CLAVIS PHARMA ASA
    Inventors: Myhren Finn, Marit Liland Sandvold, Ole Henrik Eriksen, Steinar Hagen
  • Publication number: 20100093686
    Abstract: Coatings with crystallized active agent(s) and related methods are disclosed. One method includes selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a coating composition having the selected concentration of the active agent, and applying the coating composition to the medical device. Also disclosed is an elution control coating which includes active agent that is at least about 80% crystallized within one week of being disposed on a medical device. One method enhances the formation of active agent crystals within a coating layer by adjusting the concentration of the active agent in the coating solution to reach some percentage of the active agent saturation point. Another method includes increasing the rate of active agent nucleation within the coating.
    Type: Application
    Filed: December 11, 2009
    Publication date: April 15, 2010
    Applicant: SURMODICS, INC.
    Inventors: Ralph A. Chappa, Kimberly K.M. Lindsoe
  • Publication number: 20100093684
    Abstract: The present invention relates to methods and compositions for preventing and/or treating various conditions in a patient, including for example, T-cell lymphoblastic leukemia and lymphoma as well as neurodegenerative diseases, such as for example, Alzheimer's disease. In one preferred embodiment of the invention, such methods include providing a patient with an effective amount of a combination of a NOTCH-1 inhibitor and glucocorticoid. The present invention further encompasses methods for increasing the efficacy of, and mitigating resistance to, glucocorticoids in the treatment of T-cell lymphoblastic leukemia and lymphoma, which generally include providing a patient with an effective amount of one or more NOTCH-1 inhibitors.
    Type: Application
    Filed: March 13, 2008
    Publication date: April 15, 2010
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    Inventors: Adolfo A. Ferrando, Pedro J. Real
  • Publication number: 20100068307
    Abstract: A foaming gelled composition in the form of a stable oil-in-water microemulsion comprising a fatty phase of microdroplets dispersed in an aqueous phase and a dermatological active ingredient, characterized in that it comprises a surfactant system comprising:—at least one ethoxylated nonionic surfactant;—at least one cosurfactant for stabilizing the ethoxylated nonionic surfactant;—at least one nonethoxylated hydrophilic nonionic surfactant;—at least one foaming agent chosen from the group of anionic surfactants.
    Type: Application
    Filed: January 25, 2008
    Publication date: March 18, 2010
    Applicant: PIERRE FABRE DERMO-COSMETIQUE
    Inventor: Francoise Nielloud
  • Publication number: 20100016268
    Abstract: A method and article of manufacture of treating abnormal biological tissue. The article includes use of electrochemically treated water in combination with a biologically active tissue treatment component, particularly for dermal tissue treatment. The electrochemical treatment method includes exposure of untreated water to halogen containing species, such as hypochlorous and hypobromous acid. The biologically active tissue treatment component can be a cortisone or clobetasol containing media.
    Type: Application
    Filed: September 4, 2009
    Publication date: January 21, 2010
    Inventors: Robert Lyles, JR., Robert Lyles, III
  • Publication number: 20100009952
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: May 14, 2009
    Publication date: January 14, 2010
    Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay LICHTER, Benedikt VOLLRATH, Sergio G. DURON, Michael Christopher SCAIFE, Fabrice PIU, Qiang YE, Luis A. DELLAMARY, Carl LEBEL, Andrew M. TRAMMEL, Jeffrey P. Harris
  • Publication number: 20100003231
    Abstract: It is provided an implantable device including a polymer blend that contains a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.
    Type: Application
    Filed: September 11, 2009
    Publication date: January 7, 2010
    Inventor: STEPHEN D. PACETTI
  • Patent number: 7638508
    Abstract: A compound of formula (I): wherein X represents O or S; R1 represents C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkylmethyl or C3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or R1 represents aryl, substituted aryl, heteroaryl or substituted heteroaryl; R2 represents hydrogen, methyl, which may be in either the ? or ? configuration, or methylene; R3 and R4 are the same or different and each independently represents hydrogen, halogen or a methyl group; and ?represents a single or a double bond; or a physiologically acceptable salt or solvate thereof, and pharmaceutical formulations and methods of use thereof.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: December 29, 2009
    Assignee: Glaxo Group Limited
    Inventors: Keith Biggadike, Deborah Needham
  • Publication number: 20090318399
    Abstract: The present invention discloses a novel use of a lanostane having the following formula (I) in treating a disease induced from immune disorder: wherein R1 is either H or CH3; R2 is OCOCH3, ?O or OH; R3 is H or OH; R4 is —C(?CH2)—C(CH3)2Ra, in which Ra is H or OH, or —CH?C(CH3)—Rb, in which Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH.
    Type: Application
    Filed: May 27, 2009
    Publication date: December 24, 2009
    Applicant: Sinphar Pharmaceutical Co., Ltd.
    Inventors: Hang-Ching Lin, Wen-Mein Wu
  • Publication number: 20090311182
    Abstract: This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the uptake and retention of the MR contrast agent labeled polymer with histopathological features of inflammation and local tissue damage demonstrates the practical applications of the macromolecular delivery system of the invention.
    Type: Application
    Filed: January 9, 2009
    Publication date: December 17, 2009
    Inventors: Dong Wang, Xinming Liu, Ling-Dong Quan
  • Publication number: 20090306579
    Abstract: Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.
    Type: Application
    Filed: February 24, 2009
    Publication date: December 10, 2009
    Inventors: Mike Jaffe, Gary Cook, Perry Calias, Michael A. Patane
  • Patent number: 7628978
    Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: December 8, 2009
    Assignee: Novartis Pharma AG
    Inventors: Jeffry G. Weers, Ernest G. Schutt, Luis Dellamary, Thomas E. Tarara, Alexey Kabalnov
  • Publication number: 20090298742
    Abstract: A process for forming crystalline lactose suitable for use in a pharmaceutical formulation comprises subjecting a solution comprising a plurality of nanosized lactose particles to conditions sufficient to cause crystallization to occur on the nanosized lactose particles such that a plurality of lactose particles are formed therefrom having a median diameter ranging from about 4 ?m to about 20 ?m.
    Type: Application
    Filed: August 8, 2007
    Publication date: December 3, 2009
    Applicant: GLAXO GROUP LIMITED
    Inventors: Trevor Charles Roche, Marian Wladyslaw Wood-Kaczmar, Xiang Tai, Michiel Van Oort
  • Publication number: 20090291930
    Abstract: Fibrous calcium pyrophosphate particles with a unique fibrous nanostructure are disclosed. The invention includes a composition, comprising fibrous particles, wherein the fibrous particles include fibers and the fibers include calcium and pyrophosphate. Also included are methods for making calcium pyrophosphate particles wherein solutions of calcium salt and pyrophosphate salt are combined to form the particles. Pharmaceutical compositions and methods for treating a patent using the disclosed particles are also described.
    Type: Application
    Filed: July 11, 2007
    Publication date: November 26, 2009
    Inventors: Liam M. Grover, Jake E. Barralet
  • Publication number: 20090291146
    Abstract: A process for producing lactose particles comprises combining a predetermined quantity of lactose seed particles to a first aqueous solution comprising a plurality of lactose particles to form a second solution, wherein the predetermined quantity of lactose seed particles is present in a well dispersed suspension and the first aqueous solution is saturated with said plurality of lactose particles; and subjecting the second solution to conditions sufficient to induce crystallization of the lactose seed particles to form a second plurality of lactose particles having a median particle size of about 25 microns to about 100 microns.
    Type: Application
    Filed: August 8, 2007
    Publication date: November 26, 2009
    Inventors: Trevor Charles Roche, Marian Wladyslaw Wood-Kaczmar
  • Publication number: 20090263441
    Abstract: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.
    Type: Application
    Filed: April 18, 2008
    Publication date: October 22, 2009
    Applicant: Warsaw Orthopedic, Inc.
    Inventor: William McKay
  • Publication number: 20090238859
    Abstract: The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers.
    Type: Application
    Filed: June 6, 2009
    Publication date: September 24, 2009
    Applicant: Sinexus, Inc.
    Inventors: Donald J. EATON, Mary Lynn Moran, Rodney A. Brenneman
  • Publication number: 20090216317
    Abstract: An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.
    Type: Application
    Filed: March 22, 2006
    Publication date: August 27, 2009
    Inventors: Keith R. Cromack, John L. Toner, Sandra E. Burke, Richard W. Krasula, Lewis B. Schwartz
  • Patent number: 7579335
    Abstract: The present invention is directed to compounds of formula (I): wherein R1 represents C4-C7 branched alkyl group, a bicycloalkyl group, or a C5-C6 cycloalkyl which optionally may be substituted with a C1-C4 alkyl group; R2 represents hydrogen, a methyl group, which may be in either the ? or ? configuration, or a methylene group; R3 and R4 are the same or a different group and each independently represents hydrogen, halogen or a methyl group; represents a single or a double bond; and physiologically acceptable solvates thereof, physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of the compounds.
    Type: Grant
    Filed: January 9, 2006
    Date of Patent: August 25, 2009
    Assignee: Glaxo Group Limited
    Inventors: Keith Biggadike, Deborah Needham
  • Publication number: 20090198145
    Abstract: Compositions, kits, methods, and systems to induce, maintain, monitor, and interpret a continuous, un-fragmented REM sleep state in humans, generate dreams, recover sleep, create brain neuronal plasticity and activate the brain for cognition enhancement and mood stabilization are described. If potentially combined with other medications, a platform is provided to develop new research and therapies in many fields treating the human brain. The procedure reliably and quickly generates a Continuous REM Sleep cycle of pre-determined time or indefinite duration depending on therapeutic goals, allowing the patient to experience a qualitatively superior dream sleep in a shortened period of time compared to a natural sleep cycle. Profuse positive (pleasant) dreams are produced as well. REM sleep, dreams and sleep recovery can be reliably generated, and various sleep, psychological and neurological illnesses and disorders can be treated or prevented either solely by this method or in combination with additional agents.
    Type: Application
    Filed: December 8, 2008
    Publication date: August 6, 2009
    Inventor: Harrison CHOW
  • Publication number: 20090156568
    Abstract: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described.
    Type: Application
    Filed: October 24, 2008
    Publication date: June 18, 2009
    Inventors: Partick M. Hughes, Laurent Delhaye, Michele Boix, James N. Chang, Robert T. Lyons
  • Publication number: 20090149435
    Abstract: Process for making a sterile, injectable pharmaceutical composition by combining triamcinolone, a buffer and a high viscosity hyaluronate.
    Type: Application
    Filed: December 7, 2007
    Publication date: June 11, 2009
    Inventors: Zhengjun Wang, Thomas M. McGrath, Toan N. Ha, Sam W. Lam, Bruce A. Firestone, Robert T. Lyons, James N. Chang, John T. Trogden
  • Publication number: 20090118246
    Abstract: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described.
    Type: Application
    Filed: October 23, 2008
    Publication date: May 7, 2009
    Inventors: Patrick M. Hughes, Laurent Delahaye, Michele Boix, James N. Chang, Robert T. Lyons
  • Publication number: 20090118247
    Abstract: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described.
    Type: Application
    Filed: October 24, 2008
    Publication date: May 7, 2009
    Inventors: Patrick M. Hughes, Laurent Delahaye, Michele Boix, James N. Chang, Robert T. Lyons
  • Publication number: 20090104131
    Abstract: Topically applicable compositions in the form of oil-in-water (O/W) emulsions contain a pro-penetrating system including at least one glycol and at least one additional pro-penetrating agent, a suitable emulsifying system and at least one active agent of the family of steroidal anti-inflammatory agents, and are useful e.g., for the treatment of psoriasis.
    Type: Application
    Filed: September 15, 2008
    Publication date: April 23, 2009
    Applicant: GALDERMA S.A.
    Inventors: Sandrine Segura-Orsoni, Sophie Roumec
  • Publication number: 20090104132
    Abstract: Topically applicable compositions in the form of oil-in-water emulsions contain a pro-penetrating system including at least one glycol and at least one additional pro-penetrating agent, a suitable gelling agent and at least one active agent of the family of steroidal anti-inflammatory agents and are useful, e.g., for the treatment of psoriasis.
    Type: Application
    Filed: September 15, 2008
    Publication date: April 23, 2009
    Applicant: GALDERMA S.A.
    Inventors: Sandrine Segura-Orsoni, Sophie Roumec
  • Publication number: 20090082314
    Abstract: Provided herein are compounds, compositions and methods for decreasing NF?B DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient to reduce, alleviate or treat various gastrointestinal diseases, such as inflammatory bowel disease (IBD).
    Type: Application
    Filed: June 27, 2008
    Publication date: March 26, 2009
    Inventors: John Francis Gilmer, Juan Francisco Marquez, Dermot Kelleher
  • Patent number: 7498321
    Abstract: There are provided according to the invention compounds of formula (I) wherein R1 represents C1-6 alkyl or C1-6 haloalkyl; R2 represents —C(?O)-aryl or —C(?O)-heteroaryl; R3 represents hydrogen, methyl (which may be in either the ? or ? configuration) or methylene; R4 and R5 are the same or different and each represents hydrogen or halogen; and——represents a single or a double bond; and salts and solvates thereof. There are also provided processes for preparing compounds of formula (I) and use of the compounds in therapy especially in the treatment of inflammatory and allergic conditions.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: March 3, 2009
    Assignee: Glaxo Group Limited
    Inventors: Keith Biggadike, Paul Jones, Jeremy John Payne
  • Publication number: 20090047351
    Abstract: A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w/w of lactose particles having a volume average particle size of about 70 microns or less; milling the plurality of lactose particles to yield a plurality of milled lactose particles with an average particle size, (D50), ranging from about 50 microns to about 100 microns; and classifying the plurality of milled lactose particles into at least two fractions comprising a fine fraction and a coarse fraction wherein the fine fraction has an average particle size, (D50), ranging from about 3 microns to about 50 microns, and the coarse fraction has an average particle size, (D50), ranging from about 40 microns to about 250 microns.
    Type: Application
    Filed: February 6, 2006
    Publication date: February 19, 2009
    Inventor: Stephen Newman
  • Publication number: 20090047321
    Abstract: Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents.
    Type: Application
    Filed: August 15, 2008
    Publication date: February 19, 2009
    Applicant: MEDTRONIC, INC.
    Inventors: Paul Hsien-Fu Wu, Catherine E. Taylor, Linnus Cheruiyot, Jianwei Li, Terese A. Bartlett, Matt Bergan
  • Publication number: 20090022671
    Abstract: Disclosed are methods of treating rhinosinusitis of the upper airway passages in patients afflicted with said disease, which comprises administering at least once-a-day to the surfaces of said passages of said patients an amount of aerosolized particles of mometasone furoate as a monotherapy effective for treating said disease.
    Type: Application
    Filed: July 11, 2008
    Publication date: January 22, 2009
    Inventors: Melvyn Bloom, Melvyn R. Danzig, Patricia Rohane, Heribert W. Staudinger
  • Patent number: 7479486
    Abstract: The present invention is related to novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues, their use as antiglucocorticoids for the treatment and/or prophylaxis of disease associated to an excess of glucocorticoids. In particular, the invention relates to the use of novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues for treating Cushing's syndrome, iatrogenic hypercortisolism or depression. Also the present invention is related to methods of preparing the novel 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) analogues.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: January 20, 2009
    Assignee: Laboratoires Serono SA
    Inventors: Gerardo Burton, Carlos P. Lantos, Adriana Silvia Veleiro
  • Publication number: 20090005763
    Abstract: Implantable devices and methods for delivering drugs and other substances to locations within the body of a human or animal subject to treat or diagnose sinusitis and a variety of other disorders. The invention includes implantable substance delivery devices that comprise reservoirs and barriers that control the rate at which substances pass out of the reservoirs. The delivery devices may be advanced into the body using guidewires, catheters, ports, introducers and other access apparatus. In some embodiments the delivery devices may be loaded with one or more desired substance before their introduction into the body. In other embodiments the delivery devices are loaded and/or reloaded with a desired substance after the delivery device has been introduced into the body.
    Type: Application
    Filed: April 21, 2008
    Publication date: January 1, 2009
    Applicant: ExploraMed NC1, Inc.
    Inventors: Joshua Makower, John Y. Chang, Julia D. Vrany, Amrish Jayprakash Walke
  • Publication number: 20090004243
    Abstract: The present invention is directed to polymeric materials made of biodegradable, bioabsorbable triblock copolymers and implantable devices (e.g., drug-delivery stents) containing such polymeric materials. The polymeric materials may also contain at least one therapeutic substance. The polymeric materials are formulated so as to improve the mechanical and adhesion properties, degradation, biocompatibility and drug permeability of such materials and, thus, implantable devices formed of such materials.
    Type: Application
    Filed: June 29, 2007
    Publication date: January 1, 2009
    Inventors: Stephen D. Pacetti, Mikael Trollsas
  • Publication number: 20080317805
    Abstract: This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot.
    Type: Application
    Filed: June 19, 2007
    Publication date: December 25, 2008
    Inventors: William F. McKay, John Myers Zanella, Christopher M. Hobot
  • Publication number: 20080317833
    Abstract: There are provided according to the invention pharmaceutical compositions comprising a compound of formula (I) wherein R1 represents C1-6 alkyl or C1-6 haloalkyl; R2 represents —C(?O)-aryl or —C(?O)-heteroaryl, wherein said heteroaryl is a 5 member heterocyclic aromatic ring containing 1-3 hetero atoms selected from N and S, or a 5 member heterocyclic aromatic ring containing 2-3 hetero atoms selected from N, O and S, or a 6 member heterocyclic aromatic ring containing 1-3 hetero atoms selected from N, O and S; R3 represents hydrogen, methyl (which may be in either the ? or ? configuration) or methylene; R4 and R5 are the same or different and each represents hydrogen or halogen; and represents a single or a double bond; or a physiologically acceptably salt or solvate thereof; and another therapeutically active agent; in admixture with one or more physiologically acceptable diluents or carriers.
    Type: Application
    Filed: August 28, 2008
    Publication date: December 25, 2008
    Inventors: Keith Biggadike, Paul Jones, Jeremy John Payne
  • Publication number: 20080319551
    Abstract: A poly(thioester ester amide) copolymer and method of making and using the same are disclosed.
    Type: Application
    Filed: June 25, 2007
    Publication date: December 25, 2008
    Inventors: Mikael O. Trollsas, Nam D. Pham, Michael H. Ngo, Bozena Zofia Maslanka
  • Patent number: 7468362
    Abstract: Compositions containing ?2 adrenergic agonists in combination with carbonates and carbonates of the formula and in combination with related steroid carbonates and carbonates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilator and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: December 23, 2008
    Assignee: Sepracor Inc.
    Inventors: Mark G. Currie, Steve Jones, Paul Grover, Chris H. Senanayake, Q. Kevin Fang
  • Publication number: 20080306038
    Abstract: Compositions for modulating an inflammation comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating an inflammation comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating an ocular or ophthalmic inflammation, including uveitis, vernal keratoconjunctivitis, or inflammation associated with contact lens-associated corneal infiltrates.
    Type: Application
    Filed: May 21, 2008
    Publication date: December 11, 2008
    Inventors: Jinzhong Zhang, Keith Wayne Ward
  • Publication number: 20080300229
    Abstract: Anhydrous sprayable pharmaceutical/dermatological compositions containing, as active pharmaceutical agent, a corticoid, preferably clobetasol propionate, and an oily phase, are formulated in a physiologically acceptable medium, and are useful for the treatment of a variety of conditions and afflictions, notably psoriasis.
    Type: Application
    Filed: May 29, 2008
    Publication date: December 4, 2008
    Applicant: GALDERMA S.A.
    Inventors: NATHALIE WILLCOX, SANDRINE ORSONI
  • Patent number: 7456161
    Abstract: A method for treating or preventing chronic obstructive pulmonary disease (COPD) by using as active agent a non-glucorticoid steroid, analogue thereof, such as dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S), or their salts, in an amount effective for preventing or treating COPD.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: November 25, 2008
    Assignee: Epigenesis Pharmaceuticals, LLC
    Inventor: Jonathan W. Nyce
  • Publication number: 20080286334
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Application
    Filed: October 31, 2007
    Publication date: November 20, 2008
    Applicant: ALLERGAN, INC.
    Inventors: JaneGuo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Publication number: 20080275015
    Abstract: The invention of this application relates to a formulation and method of using the formulation for the treatment of interstitial cystitis and other similar conditions of the bladder. The formulation of this invention is a highly specialized, compounded pharmaceutical that contains a combination of numerous therapeutically different medications in a unique delivery vehicle and system. The individual components of the formulation work synergistically to restore and repair each of the different issues associated with interstitial cystitis. The individual components of the formulation exist in an aqueous vehicle to facilitate drug contact with the bladder wall. The formulation is instilled directly into the bladder, commonly in a physician's office.
    Type: Application
    Filed: April 29, 2008
    Publication date: November 6, 2008
    Inventor: Jeffrey A. Potter
  • Publication number: 20080269182
    Abstract: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
    Type: Application
    Filed: May 20, 2008
    Publication date: October 30, 2008
    Inventors: James Pluda, Stanley R. Frankel, Victoria M. Richon, Steven Averbuch, Judy H. Chiao